Publisher Full Text
[Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis].Gastroenterol Hepatol. 2011 Oct; 34(8):546-50.GH
Abstract
Treatment with anti-tumor necrosis factor (TNF)-α for Crohn's disease is relatively safe, although various cutaneous adverse effects have been reported such as the development or exacerbation of anti-TNF- α-induced psoriasis, which can sometimes lead to treatment withdrawal. Therefore, new alternative treatments with new mechanisms of action are required. Ustekinumab, a monoclonal antibody against the p40 subunit of interleukin 12/23, could induce response in patients with Crohn's disease and has demonstrated efficacy in patients with psoriasis. We present the case of a woman with Crohn's disease who developed psoriasis after treatment with two anti-TNF- α drugs (infliximab and adalimumab). The patient was subsequently treated with ustekinumab with resolution or psoriasis lesions and maintenance of remission of Crohn's disease.
Links
MeSH
AdalimumabAdrenal Cortex HormonesAdultAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAzathioprineCombined Modality TherapyCrohn DiseaseDrug EruptionsDrug Therapy, CombinationFemaleHumansImmunosuppressive AgentsInfliximabInterleukin-12 Subunit p40MesalaminePhototherapyPsoriasisTumor Necrosis Factor-alphaUstekinumab
Pub Type(s)
Case Reports
English Abstract
Journal Article
Language
spa
PubMed ID
21665330
Citation
Sansó Sureda, Andrés, et al. "[Ustekinumab in a Patient With Crohn's Disease and anti-TNF-α-induced Psoriasis]." Gastroenterologia Y Hepatologia, vol. 34, no. 8, 2011, pp. 546-50.
Sansó Sureda A, Rocamora Durán V, Sapiña Camaró A, et al. [Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis]. Gastroenterol Hepatol. 2011;34(8):546-50.
Sansó Sureda, A., Rocamora Durán, V., Sapiña Camaró, A., Royo Escosa, V., & Bosque López, M. J. (2011). [Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis]. Gastroenterologia Y Hepatologia, 34(8), 546-50. https://doi.org/10.1016/j.gastrohep.2011.04.003
Sansó Sureda A, et al. [Ustekinumab in a Patient With Crohn's Disease and anti-TNF-α-induced Psoriasis]. Gastroenterol Hepatol. 2011;34(8):546-50. PubMed PMID: 21665330.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - [Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis].
AU - Sansó Sureda,Andrés,
AU - Rocamora Durán,Vicenç,
AU - Sapiña Camaró,Amparo,
AU - Royo Escosa,Vanesa,
AU - Bosque López,María José,
Y1 - 2011/06/12/
PY - 2011/01/31/received
PY - 2011/04/13/revised
PY - 2011/04/20/accepted
PY - 2011/6/14/entrez
PY - 2011/6/15/pubmed
PY - 2012/2/4/medline
SP - 546
EP - 50
JF - Gastroenterologia y hepatologia
JO - Gastroenterol Hepatol
VL - 34
IS - 8
N2 - Treatment with anti-tumor necrosis factor (TNF)-α for Crohn's disease is relatively safe, although various cutaneous adverse effects have been reported such as the development or exacerbation of anti-TNF- α-induced psoriasis, which can sometimes lead to treatment withdrawal. Therefore, new alternative treatments with new mechanisms of action are required. Ustekinumab, a monoclonal antibody against the p40 subunit of interleukin 12/23, could induce response in patients with Crohn's disease and has demonstrated efficacy in patients with psoriasis. We present the case of a woman with Crohn's disease who developed psoriasis after treatment with two anti-TNF- α drugs (infliximab and adalimumab). The patient was subsequently treated with ustekinumab with resolution or psoriasis lesions and maintenance of remission of Crohn's disease.
SN - 0210-5705
UR - https://www.unboundmedicine.com/medline/citation/21665330/[Ustekinumab_in_a_patient_with_Crohn's_disease_and_anti_TNF_α_induced_psoriasis]_
L2 - http://www.elsevier.es/en/linksolver/ft/pii/S0210-5705(11)00214-7
DB - PRIME
DP - Unbound Medicine
ER -
